Chronotherapeutic Effects of Atorvastatin Administration on Lipid Profile in Patients with Type 2 Diabetes Mellitus: A Randomized Clinical Trial

Tavanaei Fard, Sepideh; Moazezi, Zoleika; Hosseini, Akramasadat; Shirafkan, Hoda; Nosrati Andevari, Ali; Meftah, Neda

doi:10.18502/aptj.v5i4.21762

Chronotherapeutic Effects of Atorvastatin Administration on Lipid Profile in Patients with Type 2 Diabetes Mellitus: A Randomized Clinical Trial

Document Type : Original Article

Authors

Sepideh Tavanaei Fard

Zoleika Moazezi

Akramasadat Hosseini

Hoda Shirafkan

Ali Nosrati Andevari

Neda Meftah

10.18502/aptj.v5i4.21762

Abstract

Background: Type 2 diabetes mellitus (T2DM) is commonly associated with dyslipidemia and increased cardiovascular risk. Atorvastatin, a widely used statin, effectively improves lipid profiles. This study aimed to compare the effects of morning versus evening administration of atorvastatin on lipid parameters in patients with T2DM.
Materials and Methods: This randomized controlled trial enrolled 76 patients with T2DM, randomly assigned to receive Atorvastatin 40 mg either in the morning (n=38) or evening (n=38) for 4 weeks. Fasting serum triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured at baseline and post-treatment. Baseline lipid values were included as covariates in ANCOVA to compare post-treatment levels between groups.
Results: Atorvastatin significantly improved lipid profiles in both groups: LDL-C, TG, and TC decreased (P<0.05), while HDL-C increased (P<0.001) compared to baseline. After adjusting for baseline values, no significant differences were observed between morning and evening groups in LDL-C, HDL-C, TG, or TC (P>0.05).
Conclusion: Four weeks of Atorvastatin therapy significantly improved lipid profiles in patients with T2DM, irrespective of administration time. These findings suggest that dosing flexibility may enhance patient adherence without compromising efficacy.

Keywords

Type 2 diabetes mellitus

Atorvastatin

Lipid profile

Statin

Morning vs evening administration

Randomized clinical trial

Subjects